Jump to section
Inato's mission is to bring clinical research to each and every patient, regardless of who they are and where they live.
Inato is a platform that helps biopharmaceutical companies increase the pool of available patients engaged in clinical trials. The platform finds the best healthcare sites for any given study, and also ensures its partners are successfully delivering trials.
The platform was built to help physicians navigate through the hurdles of the increasingly complex research environment. Other companies advertise or match patients directly with trials, whereas Inato matches pharma companies with community sites around the world that are looking to offer more trials to their patients, which diversifies the patients available for each study.
Inato have received funding from several investors, much of which has been invested in expanding its predictive capabilities to match the right sites with the right studies. Recent initiatives include the advancement of its diversity product offering (that helps users to meet the diversity goals of their studies); the introduction of measures to increase oncology-specific enrolment; as well as moving to accelerate international growth and hiring efforts.
Kirsty
Company Specialist at Welcome to the Jungle
Mar 2023
$20m
SERIES A
Feb 2020
$14m
SERIES A
This company has top investors
Jean-David Zeitoun
(Chief Medical Officer)Medical Doctor with a degree from Sciences Po, with a PhD in Clinical Epidemiology. He is also an advisor for health industries and investment funds since 2010.
Kourosh Davarpanah
(CEO)They were formerly a Co-founder at Fleet Impact, and worked in Cryptocurrency Design at NeuCoin.